Thus, targeting IGF-1 and NF-κB in the context of obesity and elevated bioavailable IGF-1 may be an effective strategy for mimicking the anticancer effects of CR and breaking the obesity-pancreatic cancer link. Here, IGF1 is linked to obesity due to melanocortin 4 receptor deficiency.